Beiersdorf Takes an Equity Investment into S-Biomedic and Collaborates on The Skin Microbiome


Alternativ






  • Beiersdorf AG and S-Biomedic NV join forces to drive the future of skin care
  • Field of cooperation is the research into skin microbiota
  • Microbiome research is one of the most dynamic fields of science
Hamburg, Germany - July 18, 2017
Beiersdorf AG, Hamburg, Germany, and S-Biomedic NV, Beerse, Belgium, today announced that they have entered into a cooperation to jointly drive the future of skin care via research into skin microbiota. Accordingly, Beiersdorf has taken an equity investment into S-Biomedic in the single digit million euro range.

“Since 1882, Beiersdorf has been successfully building partnerships with suppliers, universities, research institutions, as well as individual inventors and innovators,” emphasized Ralph Gusko, Board Member for Consumer Brands at Beiersdorf. “With our investment into S-Biomedic, we open up for cooperations with start-up companies. These pioneers for future technologies will help us deliver answers for unmet consumer needs.”

While the pivotal role of the resident microbiota has been well established for the gut, skin microorganisms have largely been associated only with disease or malodor. Since the advent of next generation sequencing technologies knowledge about the delicate balance of the skin microbiota and its symbiotic effect on the skin’s metabolism is growing exponentially. S-Biomedic has earned the position of being a frontrunner in this field.

“Skin Care is on the verge of disruption and will hugely benefit from the dramatic progress in life science research. Microbiome research is one of the most dynamic fields, and we need to deeply look at it for innovative offers for our consumers,” said Dr. May Shana’a, Senior Corporate Vice President of R&D for Beiersdorf. “We are delighted to tap into Beiersdorf’s vast experience in skin care to take our research to the next stage of commercialization with maximum speed and efficiency,” said Veronika Oudova, CEO of S-Biomedic.


About S-Biomedic
S-Biomedic is a Belgium based life science company exploring the unexploited cosmetic and therapeutic potential of the skin microbiome. The skin microbiome – a habitat of billions of beneficial and harmful bacteria – contributes to a healthy skin. An imbalance of these bacteria can lead to a variety of skin problems. The skin microbiome offers unparalleled skincare and clinical opportunities for a wide range of unmet medical conditions. This represents a unique opportunity for the commercial development of break-through cosmetic and dermatological products. In this field, S-Biomedic has developed a lead program focusing on acne. Simultaneously, two early stage concept development programs have been initiated focusing on ageing and dandruff. S-Biomedic is a resident at Johnson & Johnson Innovation, JLABS in Beerse (JLABS @ BE). More information on www.sbiomedic.com.

About Beiersdorf AG
Beiersdorf AG is a leading provider of innovative, high-quality skin care products and has over 135 years of experience in this market segment. The Hamburg-based company has around 19,000 employees worldwide and is listed on the DAX, the German benchmark equities index. Beiersdorf generated sales of €7.1 billion in financial year 2017. NIVEA, the world’s No. 1 skin care brand*, is the cornerstone of the company’s brand portfolio, which also includes brands such as Labello, Florena, 8x4, Hidrofugal, atrix, Aquaphor, SLEK and Maestro. Beiersdorf’s wholly owned affiliate tesa SE, another globally leading manufacturer in its field, supplies self-adhesive products and system solutions to industry, craft businesses, and consumers.

* Source: Euromonitor International Limited; NIVEA by umbrella brand name in the categories Body Care, Face Care and Hand Care; in retail value terms, 2017.

« back